Cargando…
A novel messenger RNA signature as a prognostic biomarker for predicting relapse in pancreatic ductal adenocarcinoma
Pancreatic ductal adenocarcinoma (PDAC) death rate and recurrence rate have remained obstinately high. Current methods can not satisfy the need of predicting cancer relapse accurately. Utilizing expression profiles of 10 GEO datasets (N = 774), we identified 154 differentially expressed genes (DEGs)...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5762289/ https://www.ncbi.nlm.nih.gov/pubmed/29340021 http://dx.doi.org/10.18632/oncotarget.22861 |
_version_ | 1783291653364121600 |
---|---|
author | Shi, Guodong Zhang, Jingjing Lu, Zipeng Liu, Dongfang Wu, Yang Wu, Pengfei Yin, Jie Yuan, Hao Zhu, Qicong Chen, Lei Fu, Yue Peng, Yunpeng Wang, Yan Jiang, Kuirong Miao, Yi |
author_facet | Shi, Guodong Zhang, Jingjing Lu, Zipeng Liu, Dongfang Wu, Yang Wu, Pengfei Yin, Jie Yuan, Hao Zhu, Qicong Chen, Lei Fu, Yue Peng, Yunpeng Wang, Yan Jiang, Kuirong Miao, Yi |
author_sort | Shi, Guodong |
collection | PubMed |
description | Pancreatic ductal adenocarcinoma (PDAC) death rate and recurrence rate have remained obstinately high. Current methods can not satisfy the need of predicting cancer relapse accurately. Utilizing expression profiles of 10 GEO datasets (N = 774), we identified 154 differentially expressed genes (DEGs) between PDAC and normal pancreas tissue or paracancerous tissue. Next we built a 16-mRNA-based signature by means of the LASSO COX regression model. We also validated the prognostic value of the signature. Patients were classified into high-risk and low-risk group according to the signature risk score; 1 year RFS was 45% (95% CI: 31.6%–63.9%) for high-risk group in contrast to 92.5% (95% CI: 86.3%–99.1%) for low-risk group. Moreover, it could predict RFS well in cases with the receipt of different treatment modalities. The 16-mRNA-based signature was an independent and powerful prognostic biomarker for RFS for PDAC patients (HR = 7.74, 95% CI: 3.25–18.45, p < 0.0001). |
format | Online Article Text |
id | pubmed-5762289 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Impact Journals LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-57622892018-01-16 A novel messenger RNA signature as a prognostic biomarker for predicting relapse in pancreatic ductal adenocarcinoma Shi, Guodong Zhang, Jingjing Lu, Zipeng Liu, Dongfang Wu, Yang Wu, Pengfei Yin, Jie Yuan, Hao Zhu, Qicong Chen, Lei Fu, Yue Peng, Yunpeng Wang, Yan Jiang, Kuirong Miao, Yi Oncotarget Research Paper Pancreatic ductal adenocarcinoma (PDAC) death rate and recurrence rate have remained obstinately high. Current methods can not satisfy the need of predicting cancer relapse accurately. Utilizing expression profiles of 10 GEO datasets (N = 774), we identified 154 differentially expressed genes (DEGs) between PDAC and normal pancreas tissue or paracancerous tissue. Next we built a 16-mRNA-based signature by means of the LASSO COX regression model. We also validated the prognostic value of the signature. Patients were classified into high-risk and low-risk group according to the signature risk score; 1 year RFS was 45% (95% CI: 31.6%–63.9%) for high-risk group in contrast to 92.5% (95% CI: 86.3%–99.1%) for low-risk group. Moreover, it could predict RFS well in cases with the receipt of different treatment modalities. The 16-mRNA-based signature was an independent and powerful prognostic biomarker for RFS for PDAC patients (HR = 7.74, 95% CI: 3.25–18.45, p < 0.0001). Impact Journals LLC 2017-12-02 /pmc/articles/PMC5762289/ /pubmed/29340021 http://dx.doi.org/10.18632/oncotarget.22861 Text en Copyright: © 2017 Shi et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Paper Shi, Guodong Zhang, Jingjing Lu, Zipeng Liu, Dongfang Wu, Yang Wu, Pengfei Yin, Jie Yuan, Hao Zhu, Qicong Chen, Lei Fu, Yue Peng, Yunpeng Wang, Yan Jiang, Kuirong Miao, Yi A novel messenger RNA signature as a prognostic biomarker for predicting relapse in pancreatic ductal adenocarcinoma |
title | A novel messenger RNA signature as a prognostic biomarker for predicting relapse in pancreatic ductal adenocarcinoma |
title_full | A novel messenger RNA signature as a prognostic biomarker for predicting relapse in pancreatic ductal adenocarcinoma |
title_fullStr | A novel messenger RNA signature as a prognostic biomarker for predicting relapse in pancreatic ductal adenocarcinoma |
title_full_unstemmed | A novel messenger RNA signature as a prognostic biomarker for predicting relapse in pancreatic ductal adenocarcinoma |
title_short | A novel messenger RNA signature as a prognostic biomarker for predicting relapse in pancreatic ductal adenocarcinoma |
title_sort | novel messenger rna signature as a prognostic biomarker for predicting relapse in pancreatic ductal adenocarcinoma |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5762289/ https://www.ncbi.nlm.nih.gov/pubmed/29340021 http://dx.doi.org/10.18632/oncotarget.22861 |
work_keys_str_mv | AT shiguodong anovelmessengerrnasignatureasaprognosticbiomarkerforpredictingrelapseinpancreaticductaladenocarcinoma AT zhangjingjing anovelmessengerrnasignatureasaprognosticbiomarkerforpredictingrelapseinpancreaticductaladenocarcinoma AT luzipeng anovelmessengerrnasignatureasaprognosticbiomarkerforpredictingrelapseinpancreaticductaladenocarcinoma AT liudongfang anovelmessengerrnasignatureasaprognosticbiomarkerforpredictingrelapseinpancreaticductaladenocarcinoma AT wuyang anovelmessengerrnasignatureasaprognosticbiomarkerforpredictingrelapseinpancreaticductaladenocarcinoma AT wupengfei anovelmessengerrnasignatureasaprognosticbiomarkerforpredictingrelapseinpancreaticductaladenocarcinoma AT yinjie anovelmessengerrnasignatureasaprognosticbiomarkerforpredictingrelapseinpancreaticductaladenocarcinoma AT yuanhao anovelmessengerrnasignatureasaprognosticbiomarkerforpredictingrelapseinpancreaticductaladenocarcinoma AT zhuqicong anovelmessengerrnasignatureasaprognosticbiomarkerforpredictingrelapseinpancreaticductaladenocarcinoma AT chenlei anovelmessengerrnasignatureasaprognosticbiomarkerforpredictingrelapseinpancreaticductaladenocarcinoma AT fuyue anovelmessengerrnasignatureasaprognosticbiomarkerforpredictingrelapseinpancreaticductaladenocarcinoma AT pengyunpeng anovelmessengerrnasignatureasaprognosticbiomarkerforpredictingrelapseinpancreaticductaladenocarcinoma AT wangyan anovelmessengerrnasignatureasaprognosticbiomarkerforpredictingrelapseinpancreaticductaladenocarcinoma AT jiangkuirong anovelmessengerrnasignatureasaprognosticbiomarkerforpredictingrelapseinpancreaticductaladenocarcinoma AT miaoyi anovelmessengerrnasignatureasaprognosticbiomarkerforpredictingrelapseinpancreaticductaladenocarcinoma AT shiguodong novelmessengerrnasignatureasaprognosticbiomarkerforpredictingrelapseinpancreaticductaladenocarcinoma AT zhangjingjing novelmessengerrnasignatureasaprognosticbiomarkerforpredictingrelapseinpancreaticductaladenocarcinoma AT luzipeng novelmessengerrnasignatureasaprognosticbiomarkerforpredictingrelapseinpancreaticductaladenocarcinoma AT liudongfang novelmessengerrnasignatureasaprognosticbiomarkerforpredictingrelapseinpancreaticductaladenocarcinoma AT wuyang novelmessengerrnasignatureasaprognosticbiomarkerforpredictingrelapseinpancreaticductaladenocarcinoma AT wupengfei novelmessengerrnasignatureasaprognosticbiomarkerforpredictingrelapseinpancreaticductaladenocarcinoma AT yinjie novelmessengerrnasignatureasaprognosticbiomarkerforpredictingrelapseinpancreaticductaladenocarcinoma AT yuanhao novelmessengerrnasignatureasaprognosticbiomarkerforpredictingrelapseinpancreaticductaladenocarcinoma AT zhuqicong novelmessengerrnasignatureasaprognosticbiomarkerforpredictingrelapseinpancreaticductaladenocarcinoma AT chenlei novelmessengerrnasignatureasaprognosticbiomarkerforpredictingrelapseinpancreaticductaladenocarcinoma AT fuyue novelmessengerrnasignatureasaprognosticbiomarkerforpredictingrelapseinpancreaticductaladenocarcinoma AT pengyunpeng novelmessengerrnasignatureasaprognosticbiomarkerforpredictingrelapseinpancreaticductaladenocarcinoma AT wangyan novelmessengerrnasignatureasaprognosticbiomarkerforpredictingrelapseinpancreaticductaladenocarcinoma AT jiangkuirong novelmessengerrnasignatureasaprognosticbiomarkerforpredictingrelapseinpancreaticductaladenocarcinoma AT miaoyi novelmessengerrnasignatureasaprognosticbiomarkerforpredictingrelapseinpancreaticductaladenocarcinoma |